Literature DB >> 15545167

Reduced joint pain after short-term duodenal administration of seal oil in patients with inflammatory bowel disease: comparison with soy oil.

T Bjørkkjaer1, L A Brunborg, G Arslan, R A Lind, J G Brun, M Valen, B Klementsen, A Berstad, L Frøyland.   

Abstract

BACKGROUND: Rheumatic joint pain is a common extra-intestinal complication of inflammatory bowel disease (IBD). Because the high ratio of n-6 to n-3 fatty acids (FAs) of the Western diet might promote rheumatic disorders, we sought to compare the effects of short-term duodenal administration of n-3-rich seal oil and n-6-rich soy oil on IBD-related joint pain.
METHODS: Nineteen patients with IBD-related joint pain were included in the study; 9 had Crohn disease and 10 had ulcerative colitis. Ten millilitres seal oil (n = 10) or soy oil (n = 9) was self-administered through a nasoduodenal feeding tube 3 times daily for 10 days.
RESULTS: Compared with soy oil treatment, seal oil significantly reduced the duration of morning stiffness (P = 0.024), number of tender joints (P = 0.035), intensity of pain (P = 0.025) and the doctor's scoring of rheumatic disease activity (P = 0.025) at the end of the 10-day treatment period. Analysis of the effects as area under the curve (area between the curve and baseline, zero) for the entire period from start of treatment until 6 months' post-treatment suggested a long-lasting beneficial effect of seal oil administration on joint pain, whereas soy oil tended (not significantly) to aggravate the condition. Consistently, the serum ratios of n-6 to n-3 FAs (P < 0.01) and arachidonic acid to eicosapentaenoic acid (P < 0.01) were reduced after treatment with seal oil.
CONCLUSION: The results suggest distinctive, differential prolonged effects on IBD-related joint pain of short-term duodenal administration of n-3-rich seal oil (significant improvement) and n-6-rich soy oil (tendency to exacerbation).

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15545167     DOI: 10.1080/00365520410009429

Source DB:  PubMed          Journal:  Scand J Gastroenterol        ISSN: 0036-5521            Impact factor:   2.423


  10 in total

1.  Dry Eye Assessment and Management (DREAM©) Study: Study design and baseline characteristics.

Authors:  Penny A Asbell; Maureen G Maguire; Ellen Peskin; Vatinee Y Bunya; Eric J Kuklinski
Journal:  Contemp Clin Trials       Date:  2018-06-06       Impact factor: 2.226

2.  Antioxidant Supplements and Gastrointestinal Diseases: A Critical Appraisal.

Authors:  Islam Khan; Sue E Samson; Ashok Kumar Grover
Journal:  Med Princ Pract       Date:  2017-03-08       Impact factor: 1.927

3.  Effects of seal oil and tuna-fish oil on platelet parameters and plasma lipid levels in healthy subjects.

Authors:  Neil J Mann; Stella L O'Connell; Kylie M Baldwin; Indu Singh; Barbara J Meyer
Journal:  Lipids       Date:  2010-07-23       Impact factor: 1.880

Review 4.  The potential interactions between polyunsaturated fatty acids and colonic inflammatory processes.

Authors:  S C Mills; A C Windsor; S C Knight
Journal:  Clin Exp Immunol       Date:  2005-11       Impact factor: 4.330

5.  Duodenal administered seal oil for patients with subjective food hypersensitivity: an explorative open pilot study.

Authors:  Kine Gregersen; Ragna A Lind; Jørgen Valeur; Tormod Bjørkkjær; Arnold Berstad; Gülen Arslan Lied
Journal:  Int J Gen Med       Date:  2010-12-06

6.  Protocol for the Cognitive Interventions and Nutritional Supplements (CINS) trial: a randomized controlled multicenter trial of a brief intervention (BI) versus a BI plus cognitive behavioral treatment (CBT) versus nutritional supplements for patients with long-lasting muscle and back pain.

Authors:  Silje E Reme; Torill H Tveito; Trudie Chalder; Tormod Bjørkkjaer; Aage Indahl; Jens I Brox; Egil Fors; Eli M Hagen; Hege R Eriksen
Journal:  BMC Musculoskelet Disord       Date:  2011-07-07       Impact factor: 2.362

7.  Short-term duodenal seal oil administration normalised n-6 to n-3 fatty acid ratio in rectal mucosa and ameliorated bodily pain in patients with inflammatory bowel disease.

Authors:  Tormod Bjørkkjaer; Johan G Brun; Merete Valen; Gülen Arslan; Ragna Lind; Linn A Brunborg; Arnold Berstad; Livar Frøyland
Journal:  Lipids Health Dis       Date:  2006-03-20       Impact factor: 3.876

Review 8.  Fat meets the cholinergic antiinflammatory pathway.

Authors:  Kevin J Tracey
Journal:  J Exp Med       Date:  2005-10-17       Impact factor: 14.307

Review 9.  Actors and Factors in the Resolution of Intestinal Inflammation: Lipid Mediators As a New Approach to Therapy in Inflammatory Bowel Diseases.

Authors:  Federica Ungaro; Federica Rubbino; Silvio Danese; Silvia D'Alessio
Journal:  Front Immunol       Date:  2017-10-23       Impact factor: 7.561

Review 10.  Omega 3 fatty acids (fish oil) for maintenance of remission in Crohn's disease.

Authors:  Raffi Lev-Tzion; Anne Marie Griffiths; Oren Leder; Dan Turner
Journal:  Cochrane Database Syst Rev       Date:  2014-02-28
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.